This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Aerie Pharmaceuticals Gestion

Gestion contrôle des critères 1/4

Informations clés

Raj Kannan

Directeur général

US$4.3m

Rémunération totale

Pourcentage du salaire du PDG	0.6%
Durée du mandat du directeur général	less than a year
Propriété du PDG	0.4%
Durée moyenne d'occupation des postes de direction	less than a year
Durée moyenne du mandat des membres du conseil d'administration	7.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Raj Kannan a-t-elle évolué par rapport aux bénéfices de Aerie Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2022	n/a	n/a	-US$37m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$69m
Dec 31 2021	US$4m	US$24k	-US$75m

Rémunération vs marché: Raj's total compensation ($USD4.25M) is above average for companies of similar size in the German market ($USD1.32M).

Rémunération et revenus: Insufficient data to compare Raj's compensation with company performance.

PDG

Raj Kannan (58 yo)

less than a year

Titularisation

US$4,253,490

Compensation

Mr. Raj Kannan serves as Chief Executive Officer and Director at Aerie Pharmaceuticals, Inc since December 20, 2021 and serves as its Principal Financial Officer since March 1, 2022. He has been Chief Exec...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Raj Kannan	CEO, Principal Financial Officer & Director	less than a year	US$4.25m	0.44% € 3.2m
Casey Kopczynski	Co-Founder	17.8yrs	US$1.46m	0.57% € 4.2m
John LaRocca	General Counsel & Secretary	4.8yrs	US$1.45m	0.11% € 797.5k
Peter Lang	Chief Financial Officer	less than a year	pas de données	0.18% € 1.3m
Michelle Senchyna	Head of Clinical Development & Operations	no data	pas de données	pas de données
Jeffrey Calabrese	VP of Finance & Principal Accounting Officer	3.4yrs	pas de données	0.038% € 276.6k
Carolyn McAuliffe	Senior Director of Communications	1.2yrs	pas de données	pas de données
Wanda Francies	Head of Human Resources	less than a year	pas de données	pas de données
Marvin Garrett	Head of Regulatory Affairs & Quality Assurance	less than a year	pas de données	pas de données
Craig Skenes	Head of Business Development	less than a year	pas de données	pas de données
Kenneth Ruettimann	Head of Manufacturing	less than a year	pas de données	pas de données
Gary Sternberg	Chief Medical Officer	less than a year	pas de données	pas de données

0.8yrs

Durée moyenne de l'emploi

57.5yo

Âge moyen

Gestion expérimentée: 0P0's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Raj Kannan	CEO, Principal Financial Officer & Director	less than a year	US$4.25m	0.44% € 3.2m
Benjamin McGraw	Independent Chairman	8.2yrs	US$1.77m	0.085% € 624.9k
David Gryska	Independent Director	4.2yrs	US$168.67k	0.027% € 200.8k
Mechiel M. Toit	Independent Director	7.4yrs	US$163.67k	0.033% € 239.6k
Peter McDonnell	Independent Director	2.4yrs	US$161.17k	0.016% € 119.0k
Richard Croarkin	Independent Director	7.5yrs	US$169.05k	0.033% € 239.6k
Julie McHugh	Independent Director	7.4yrs	US$173.67k	0.033% € 239.6k

7.4yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: 0P0's board of directors are considered experienced (7.4 years average tenure).

This company is no longer active

Aerie Pharmaceuticals Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Aerie Pharmaceuticals, Inc. Announces Management Changes

Dr. Gerald D. Cagle to Not Stand for Re-Election as Director of Aerie Pharmaceuticals, Inc

Aerie Pharmaceuticals, Inc. Announces Retirement of Kathleen McGinley as Chief Human Resources Officer and Vice President, Corporate Services, Effective March 31, 2022

Aerie Pharmaceuticals, Inc. Announces Executive Changes

Aerie Pharmaceuticals, Inc. Announces Executive Changes

Insufficient new directors

Recent updates

Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from NASDAQ Composite Index

Aerie Pharmaceuticals, Inc. Announces Management Changes

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.86 loss in 3Q 2021)

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.84 loss in 2Q 2021)

Aerie Pharmaceuticals, Inc. Announces First Participant Dosed in the Comet-3 Study of Ar-15512 for the Treatment of Dry Eye Disease

Aerie Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease

Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease

First quarter 2022 earnings released: US$0.76 loss per share (vs US$0.91 loss in 1Q 2021)

No longer forecast to breakeven

Dr. Gerald D. Cagle to Not Stand for Re-Election as Director of Aerie Pharmaceuticals, Inc

Aerie Pharmaceuticals, Inc. Announces Retirement of Kathleen McGinley as Chief Human Resources Officer and Vice President, Corporate Services, Effective March 31, 2022

Aerie Pharmaceuticals, Inc. Announces Executive Changes

Aerie Pharmaceuticals, Inc. Announces Executive Changes

No longer forecast to breakeven

Aerie Pharmaceuticals, Inc. Announces Revenue Guidance for the Full Year for 2022

Aerie Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Forecast to breakeven in 2024

Insufficient new directors

Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.86 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$1.05 loss in 2Q 2020)

CFO, Secretary & Treasurer Richard Rubino has left the company

Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan

Forecast to breakeven in 2024

New 90-day high: €16.00

Full year 2020 earnings released: US$3.99 loss per share (vs US$4.39 loss in FY 2019)

Revenue beats expectations

Aerie Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €11.70

Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

New 90-day high: €11.60

Aerie Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Roclanda® in the European Union

Third quarter 2020 earnings released: US$0.86 loss per share

Revenue beats expectations

Aerie Pharmaceuticals, Inc. Announces Commencement of Comet-1

Aerie Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €8.15

Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease

Aerie Pharmaceuticals, Inc. Announces Successful Interim 90-Day Topline Data from Its Six-Month Phase 3B Clinical Trial in Europe Known as Mercury 3

New 90-day low - €8.85

New 90-day low - €9.55

First half earnings released

New 90-day low - €10.00

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen